The Prognostic and Therapeutic Implications of the Chemoresistance Gene BIRC5 in Triple-Negative Breast Cancer
Chemoresistance affects TNBC patient treatment responses. Therefore, identifying the chemoresistant gene provides a new approach to understanding chemoresistance in TNBC. BIRC5 was examined in the current study as a tool for predicting the prognosis of TNBC patients and assisting in developing alter...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/21/5180 |
| _version_ | 1797468884601667584 |
|---|---|
| author | Getinet M. Adinew Samia Messeha Equar Taka Karam F. A. Soliman |
| author_facet | Getinet M. Adinew Samia Messeha Equar Taka Karam F. A. Soliman |
| author_sort | Getinet M. Adinew |
| collection | DOAJ |
| description | Chemoresistance affects TNBC patient treatment responses. Therefore, identifying the chemoresistant gene provides a new approach to understanding chemoresistance in TNBC. BIRC5 was examined in the current study as a tool for predicting the prognosis of TNBC patients and assisting in developing alternative therapies using online database tools. According to the examined studies, BIRC5 was highly expressed in 45 to 90% of TNBC patients. BIRC5 is not only abundantly expressed but also contributes to resistance to chemotherapy, anti-HER2 therapy, and radiotherapy. Patients with increased expression of BIRC5 had a median survival of 31.2 months compared to 85.8 months in low-expression counterparts (HR, 1.73; CI, 1.4–2.13; <i>p</i> = 2.5 × 10<sup>−7</sup>). The overall survival, disease-free survival, relapse-free survival, distant metastasis-free survival, and the complete pathological response of TNBC patients with high expression of BIRC5 who received any chemotherapy (Taxane, Ixabepilone, FAC, CMF, FEC, Anthracycline) and anti-HER2 therapy (Trastuzumab, Lapatinib) did not differ significantly from those patients receiving any other treatment. Data obtained indicate that the BIRC5 promoter region was substantially methylated, and hypermethylation was associated with higher BIRC5 mRNA expression (<i>p</i> < 0.05). The findings of this study outline the role of BIRC5 in chemotherapy-induced resistance of TNBC, further indicating that BIRC5 may serve as a promising prognostic biomarker that contributes to chemoresistance and could be a possible therapeutic target. Meanwhile, several in vitro studies show that flavonoids were highly effective in inhibiting BIRC5 in genetically diverse TNBC cells. Therefore, flavonoids would be a promising strategy for preventing and treating TNBC patients with the BIRC5 molecule. |
| first_indexed | 2024-03-09T19:13:40Z |
| format | Article |
| id | doaj.art-d55b95295be34e6ca09cb91975e6d475 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T19:13:40Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-d55b95295be34e6ca09cb91975e6d4752023-11-24T04:00:24ZengMDPI AGCancers2072-66942022-10-011421518010.3390/cancers14215180The Prognostic and Therapeutic Implications of the Chemoresistance Gene BIRC5 in Triple-Negative Breast CancerGetinet M. Adinew0Samia Messeha1Equar Taka2Karam F. A. Soliman3Division of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A & M University, Tallahassee, FL 32307, USADivision of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A & M University, Tallahassee, FL 32307, USADivision of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A & M University, Tallahassee, FL 32307, USADivision of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A & M University, Tallahassee, FL 32307, USAChemoresistance affects TNBC patient treatment responses. Therefore, identifying the chemoresistant gene provides a new approach to understanding chemoresistance in TNBC. BIRC5 was examined in the current study as a tool for predicting the prognosis of TNBC patients and assisting in developing alternative therapies using online database tools. According to the examined studies, BIRC5 was highly expressed in 45 to 90% of TNBC patients. BIRC5 is not only abundantly expressed but also contributes to resistance to chemotherapy, anti-HER2 therapy, and radiotherapy. Patients with increased expression of BIRC5 had a median survival of 31.2 months compared to 85.8 months in low-expression counterparts (HR, 1.73; CI, 1.4–2.13; <i>p</i> = 2.5 × 10<sup>−7</sup>). The overall survival, disease-free survival, relapse-free survival, distant metastasis-free survival, and the complete pathological response of TNBC patients with high expression of BIRC5 who received any chemotherapy (Taxane, Ixabepilone, FAC, CMF, FEC, Anthracycline) and anti-HER2 therapy (Trastuzumab, Lapatinib) did not differ significantly from those patients receiving any other treatment. Data obtained indicate that the BIRC5 promoter region was substantially methylated, and hypermethylation was associated with higher BIRC5 mRNA expression (<i>p</i> < 0.05). The findings of this study outline the role of BIRC5 in chemotherapy-induced resistance of TNBC, further indicating that BIRC5 may serve as a promising prognostic biomarker that contributes to chemoresistance and could be a possible therapeutic target. Meanwhile, several in vitro studies show that flavonoids were highly effective in inhibiting BIRC5 in genetically diverse TNBC cells. Therefore, flavonoids would be a promising strategy for preventing and treating TNBC patients with the BIRC5 molecule.https://www.mdpi.com/2072-6694/14/21/5180breast cancertriple-negative breast cancersurvivingBIRC5 |
| spellingShingle | Getinet M. Adinew Samia Messeha Equar Taka Karam F. A. Soliman The Prognostic and Therapeutic Implications of the Chemoresistance Gene BIRC5 in Triple-Negative Breast Cancer Cancers breast cancer triple-negative breast cancer surviving BIRC5 |
| title | The Prognostic and Therapeutic Implications of the Chemoresistance Gene BIRC5 in Triple-Negative Breast Cancer |
| title_full | The Prognostic and Therapeutic Implications of the Chemoresistance Gene BIRC5 in Triple-Negative Breast Cancer |
| title_fullStr | The Prognostic and Therapeutic Implications of the Chemoresistance Gene BIRC5 in Triple-Negative Breast Cancer |
| title_full_unstemmed | The Prognostic and Therapeutic Implications of the Chemoresistance Gene BIRC5 in Triple-Negative Breast Cancer |
| title_short | The Prognostic and Therapeutic Implications of the Chemoresistance Gene BIRC5 in Triple-Negative Breast Cancer |
| title_sort | prognostic and therapeutic implications of the chemoresistance gene birc5 in triple negative breast cancer |
| topic | breast cancer triple-negative breast cancer surviving BIRC5 |
| url | https://www.mdpi.com/2072-6694/14/21/5180 |
| work_keys_str_mv | AT getinetmadinew theprognosticandtherapeuticimplicationsofthechemoresistancegenebirc5intriplenegativebreastcancer AT samiamesseha theprognosticandtherapeuticimplicationsofthechemoresistancegenebirc5intriplenegativebreastcancer AT equartaka theprognosticandtherapeuticimplicationsofthechemoresistancegenebirc5intriplenegativebreastcancer AT karamfasoliman theprognosticandtherapeuticimplicationsofthechemoresistancegenebirc5intriplenegativebreastcancer AT getinetmadinew prognosticandtherapeuticimplicationsofthechemoresistancegenebirc5intriplenegativebreastcancer AT samiamesseha prognosticandtherapeuticimplicationsofthechemoresistancegenebirc5intriplenegativebreastcancer AT equartaka prognosticandtherapeuticimplicationsofthechemoresistancegenebirc5intriplenegativebreastcancer AT karamfasoliman prognosticandtherapeuticimplicationsofthechemoresistancegenebirc5intriplenegativebreastcancer |